FDA advisors back Lilly’s Alzheimer’s drug, setting stage for approval after delay

An FDA advisory committee gave its strong backing to Eli Lilly’s Alzheimer’s drug donanemab, giving further support for the agency’s expected approval after a surprise …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

The clock is ticking, and Cytokinetics is running out of December

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here

December 22, 2023

The dropped call that took down Centene’s Medicare Advantage star ratings

You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox

October 28, 2024

New insights into immune mechanisms that prevent cancer metastasis

Metastatic disease-;when cancer spreads from the primary tumor to other parts of the body-;is the cause of most cancer deaths.

October 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.